Axel Hoos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Axel Hoos has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Michele Maio
Center for Immuno-Oncology, University Hospital of Siena, University of Siena, Siena, Italy
97 shared publications - Sapna Yadavilli
GSK, Collegeville, Pennsylvania
97 shared publications - Ashleigh Hahn
GSK, Collegeville, Pennsylvania
96 shared publications - Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
96 shared publications - David C. Turner
Clinical Pharmacology Genentech South San Francisco California USA
96 shared publications - Jafar Sadik Shaik
GSK, Collegeville, Pennsylvania
96 shared publications
Latest Publications
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (10) , 2131-2149
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science
Small-molecule drugs have enabled the practice of precision oncology for genetically defined patient populations since the first approval of imatinib in 2001. Scientific and technology advances over this 20-year period have driven the evolution of cancer biology, medicinal chemistry, and data science. Collectively, these advances provide tools to more consistently design best-in-class small-molecule drugs against known, previously undruggable, and novel cancer targets. The integration of these tools and their customization in the hands of skilled drug hunters will be necessary to enable the discovery of transformational therapies for patients across a wider spectrum of cancers. Significance: Target-centric small-molecule drug discovery necessitates the consideration of multiple approaches to identify chemical matter that can be optimized into drug candidates. To do this successfully and consistently, drug hunters require a comprehensive toolbox to avoid following the “law of instrument” or Maslow's hammer concept where only one tool is applied regardless of the requirements of the task. Combining our ever-increasing understanding of cancer and cancer targets with the technological advances in drug discovery described below will accelerate the next generation of small-molecule drugs in oncology.
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (10) , 2131-2149
Open AccessPrecision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science
Small-molecule drugs have enabled the practice of precision oncology for genetically defined patient populations since the first approval of imatinib in 2001. Scientific and technology advances over this 20-year period have driven the evolution of cancer biology, medicinal chemistry, and data science. Collectively, these advances provide tools to more consistently design best-in-class small-molecule drugs against known, previously undruggable, and novel cancer targets. The integration of these tools and their customization in the hands of skilled drug hunters will be necessary to enable the discovery of transformational therapies for patients across a wider spectrum of cancers. Significance: Target-centric small-molecule drug discovery necessitates the consideration of multiple approaches to identify chemical matter that can be optimized into drug candidates. To do this successfully and consistently, drug hunters require a comprehensive toolbox to avoid following the “law of instrument” or Maslow's hammer concept where only one tool is applied regardless of the requirements of the task. Combining our ever-increasing understanding of cancer and cancer targets with the technological advances in drug discovery described below will accelerate the next generation of small-molecule drugs in oncology.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Movie 1 Legend from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Expression dynamics and cellular localization of ICOS.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie 1 Legend from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Expression dynamics and cellular localization of ICOS.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Gene expression in human T-cell
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Gene expression in human T-cell
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab. A, Clinical history and treatment details for a patient with melanoma who received feladilimab monotherapy and a patient with oropharyngeal squamous cell carcinoma who received feladilimab in combination with pembrolizumab. Tumor sample immunohistochemistry and expression of markers for TIL activation, cytotoxic function and proliferation for the monotherapy case study (B) and the combination therapy case study (C). See Supplementary Fig. S11B for CT imaging of tumor lesions for the patient with oropharyngeal squamous cell carcinoma. CPS, combined positive score; CT, computed tomography; HLA-DR, human leukocyte antigen-DR; HPV, human papillomavirus; PD-L1, programmed death ligand-1; TIL, tumor-infiltrating lymphocyte.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab. A, Clinical history and treatment details for a patient with melanoma who received feladilimab monotherapy and a patient with oropharyngeal squamous cell carcinoma who received feladilimab in combination with pembrolizumab. Tumor sample immunohistochemistry and expression of markers for TIL activation, cytotoxic function and proliferation for the monotherapy case study (B) and the combination therapy case study (C). See Supplementary Fig. S11B for CT imaging of tumor lesions for the patient with oropharyngeal squamous cell carcinoma. CPS, combined positive score; CT, computed tomography; HLA-DR, human leukocyte antigen-DR; HPV, human papillomavirus; PD-L1, programmed death ligand-1; TIL, tumor-infiltrating lymphocyte.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Example TIL marker expression phenotypes from clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Example TIL marker expression phenotypes from clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
ICOS agonist mAbs demonstrate single-agent antitumor activity. A–C, EMT6 (subcutaneous) tumor-bearing BALB/c mice were administered intraperitoneally biweekly with anti-mouse ICOS mAb [7E.17G9 (mIgG1)] or isotype control (mIgG1) for a total of six doses and evaluated for tumor growth (A), survival (B), and pharmacodynamic changes (C) within tumors. Each line in A represents an individual mouse (n = 10/group). Number of tumor-free mice at study termination are indicated within each subpanel. B, Kaplan–Meier plot illustrating OS in A. C, Percentage of tumor-infiltrating CD8+ T cells, Treg cells, and associated CD8:Treg cell ratio 48 hours after the third dose of anti-ICOS mAb (10 μg, ∼study day 7) assessed using flow cytometry (nonspecific binding was blocked with human or mouse Fc block). Each symbol represents an individual mouse. D–F, A549 (subcutaneous) tumor-bearing NSG mice were administered intraperitoneally biweekly with feladilimab or isotype control for a total of six doses. D, A549 tumor growth kinetics for controls (PBS or isotype) and feladilimab-treated groups (0.04 mg/kg, black; 0.4 mg/kg, red). Percentage of tumor-infiltrating ICOS+ CD8+ T cells (E; assessed using flow cytometry with nonspecific binding blocked using human or mouse Fc block) and associated CD8:Treg cell ratio (F) 48 hours after the fourth dose of feladilimab (∼study day 21). Data in C, D, E, and F represent the mean ± s.e.m. Significance was determined by unpaired Student t test. See Supplementary Fig. S1 for flow cytometry gating strategy for C, E, and F. CD8/Treg ratios were calculated on the basis of percent (%) positive CD8s (of live CD45+) and FoxP3/CD25+ Treg cells (of live CD45+ CD4+ cells). ICOS, inducible T-cell costimulator; i.p., intraperitoneal injection; mAb, monoclonal antibody; OS, overall survival; s.e.m., standard error of the mean.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
ICOS agonist mAbs demonstrate single-agent antitumor activity. A–C, EMT6 (subcutaneous) tumor-bearing BALB/c mice were administered intraperitoneally biweekly with anti-mouse ICOS mAb [7E.17G9 (mIgG1)] or isotype control (mIgG1) for a total of six doses and evaluated for tumor growth (A), survival (B), and pharmacodynamic changes (C) within tumors. Each line in A represents an individual mouse (n = 10/group). Number of tumor-free mice at study termination are indicated within each subpanel. B, Kaplan–Meier plot illustrating OS in A. C, Percentage of tumor-infiltrating CD8+ T cells, Treg cells, and associated CD8:Treg cell ratio 48 hours after the third dose of anti-ICOS mAb (10 μg, ∼study day 7) assessed using flow cytometry (nonspecific binding was blocked with human or mouse Fc block). Each symbol represents an individual mouse. D–F, A549 (subcutaneous) tumor-bearing NSG mice were administered intraperitoneally biweekly with feladilimab or isotype control for a total of six doses. D, A549 tumor growth kinetics for controls (PBS or isotype) and feladilimab-treated groups (0.04 mg/kg, black; 0.4 mg/kg, red). Percentage of tumor-infiltrating ICOS+ CD8+ T cells (E; assessed using flow cytometry with nonspecific binding blocked using human or mouse Fc block) and associated CD8:Treg cell ratio (F) 48 hours after the fourth dose of feladilimab (∼study day 21). Data in C, D, E, and F represent the mean ± s.e.m. Significance was determined by unpaired Student t test. See Supplementary Fig. S1 for flow cytometry gating strategy for C, E, and F. CD8/Treg ratios were calculated on the basis of percent (%) positive CD8s (of live CD45+) and FoxP3/CD25+ Treg cells (of live CD45+ CD4+ cells). ICOS, inducible T-cell costimulator; i.p., intraperitoneal injection; mAb, monoclonal antibody; OS, overall survival; s.e.m., standard error of the mean.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Flow cytometry gating strategy for ICOS on individual T cell populations.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Flow cytometry gating strategy for ICOS on individual T cell populations.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Rationale for combination of feladilimab with anti–PD-1 blockade.
- 16 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Rationale for combination of feladilimab with anti–PD-1 blockade.